Advertisement

Transfusion Medicine: The Impact of Biotechnology, Growth Factors, and Bioengineering

  • H. G. Klein
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 27)

Abstract

Basic science advances coupled with sophisticated new instrumentation have been moving the discipline of Transfusion Medicine beyond its traditional role as supplier of blood components into such evolving fields as cancer cellular biotherapy, bone marrow transplantation, and gene therapy. Bioreactor culture systems, improved techniques of cell separation, and applied molecular biology are a few of the areas that promise to revolutionize transfusion practices [[1]]. However few discoveries have made the immediate impact or captured the imagination to the extent that have a series of regulatory molecules known as cytokines, interleukins, or hematopoietic growth factors.

Keywords

Transfusion Medicine Recombinant Human Erythropoietin Adoptive Immunotherapy Myeloid Growth Factor Autologous Marrow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chernoff AI, Klein HG, Sherman LA (eds). Research opportunities in Transfusion Medicine. Transfusion 1989;29:711–42.Google Scholar
  2. 2.
    Eschbach JW, Abdulhabi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989;111:992–1000.PubMedGoogle Scholar
  3. 3.
    Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with Zidovudine. N Engl J Med 1990;322:1488–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Miller CB, Jones RJ, Piandosi S, Abeloff, Spivak JL. Decreased erythropietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Watanabe Y, Fuse K, Konishi T, et al. Autologous blood transfusion with recombinant human erythropoietin in heart operation. Ann Thorac Surg 1991;51:767–72.PubMedCrossRefGoogle Scholar
  6. 6.
    Goodnough LT, Rudnick S, Stehling LC, et al. Predeposited autologous blood for elective surgery: A national multicenter study. N Engl J Med 1989;321:1163–68.PubMedCrossRefGoogle Scholar
  7. 7.
    Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation with lymphoid cancer. N Engl J Med 1991;324:1773–78.PubMedCrossRefGoogle Scholar
  10. 10.
    Weisbart RH, Kwan L, Golde DW, Gasson JC. Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to the major physiological chemoattractants. Blood 1987;69:18–21.PubMedGoogle Scholar
  11. 11.
    Sullivan R, Fredette JP, Socinski M, et al. Enhancement of superoxide release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor. Brit J Haematol 1989;71:475–89.CrossRefGoogle Scholar
  12. 12.
    Begley CG, Lopez AF, Nicola NA, et al. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: A rapid and sensitive microassay for colony-stimulating factors. Blood 1986;68:162–66.PubMedGoogle Scholar
  13. 13.
    Smith PD, Lamerson CL, Banks SM, et al. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Inf Dis 1990;161:999–1005.CrossRefGoogle Scholar
  14. 14.
    Aglietta M, Piacibello W, Sanavio F, et al. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony stimulating factor. J Clin Invest 1988;83:551–57.CrossRefGoogle Scholar
  15. 15.
    Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophos-phamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74:1905–14.PubMedGoogle Scholar
  16. 16.
    Haas R, Ho AD, Bredthauer U, et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990:1894–98.Google Scholar
  17. 17.
    Gianni AM, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkins lymphoma. J Clin Oncol 1990;8:768–78.PubMedGoogle Scholar
  18. 18.
    Klein HG, Leitman SF. Adoptive immunotherapy in the treatment of malignant disease. Transfusion 1989;29:170–78.PubMedCrossRefGoogle Scholar
  19. 19.
    Stevenson HC, Foon KA, Sugarbaker PH. Ex vivo activation of killer monocytes and their application to the treatment of human cancer. J Clin Apheresis 1988;4:114–21.CrossRefGoogle Scholar
  20. 20.
    Topalian S, Solomon D, Avis FP, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 1988;6:839–53.PubMedGoogle Scholar
  21. 21.
    Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570–78.PubMedCrossRefGoogle Scholar
  22. 22.
    Anderson DM, Lyman SD, Baird A, et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane and soluble forms. Cell 1990;63:235.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • H. G. Klein

There are no affiliations available

Personalised recommendations